Compass Therapeutics, Inc. (CMPX), a clinical-stage biopharmaceutical company focused on oncology, announced on Wednesday the advancement of its new drug candidate, CTX-10726, a novel PD-1 x VEGF-A bispecific antibody, following a year of preclinical development. The company expects to file an Investigational New Drug or IND application for CTX-10726 by the end of 2025, with initial clinical data anticipated in 2026.
Additionally, Compass provided an update on its ongoing clinical trials. The Phase 2/3 trial of tovecimig or formerly CTX-009, a DLL4 x VEGF-A bispecific antibody, in patients with advanced biliary tract cancer or BTC is on track to provide top-line data by the end of the first quarter 2025.
Pivotal trial, known as COMPANION-002, will assess the combination of tovecimig and paclitaxel in these patients.
The company also announced plans for two Phase 2 biomarker trials scheduled to begin in mid-2025:
-- Tovecimig will be tested in DLL4-positive colorectal cancer patients in the second-line setting.
-- CTX-471, a CD137 agonist antibody, will be evaluated in NCAM/CD56-expressing tumors.
Compass is progressing with CTX-8371, a PD-1 x PD-L1 bispecific antibody, and expects to report preliminary data from its Phase 1 trial in the second half of 2025.
With an estimated $127 million in cash and marketable securities at the end of 2024, the company is well-funded, with its cash runway extending into the first quarter 2027.
"We are excited to advance CTX-10726 into clinical development and look forward to the top-line data readout for tovecimig in BTC later this quarter," said Thomas Schuetz, MD, PhD, CEO of Compass Therapeutics.
Compass Therapeutics is committed to developing innovative antibody-based therapies to address critical cancer pathways, with ongoing efforts to target both angiogenesis and immune response modulation.
The company had cash balance of $135 million in cash and marketable securities as of September 30, 2024, which is expected to provide cash runway into the first quarter of 2027.
Currently, CMPX is trading at $2 up by 35.69%.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.